Pfizer Inc
$ 26.76
2.14%
07 Aug - close price
- Market Cap 152,523,260,000 USD
- Current Price $ 26.76
- High / Low $ 26.76 / 26.05
- Stock P/E 34.31
- Book Value 14.95
- EPS 0.78
- Next Earning Report -
- Dividend Per Share $1.72
- Dividend Yield 6.56 %
- Next Dividend Date 2026-09-01
- ROA 0.06 %
- ROE 0.05 %
- 52 Week High 27.80
- 52 Week Low 22.03
About
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Analyst Target Price
$28.63
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-02-03 | 2025-11-04 | 2025-08-05 | 2025-04-29 | 2025-02-04 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-01-30 | 2023-10-31 |
| Reported EPS | 0.77 | 0.75 | 0.66 | 0.87 | 0.78 | 0.92 | 0.63 | 1.06 | 0.6 | 0.82 | 0.1 | -0.17 |
| Estimated EPS | 0.68 | 0.72 | 0.57 | 0.63 | 0.57 | 0.67 | 0.46 | 0.61 | 0.46 | 0.51 | -0.18 | -0.34 |
| Surprise | 0.09 | 0.03 | 0.09 | 0.24 | 0.21 | 0.25 | 0.17 | 0.45 | 0.14 | 0.31 | 0.28 | 0.17 |
| Surprise Percentage | 13.2353% | 4.1667% | 15.7895% | 38.0952% | 36.8421% | 37.3134% | 36.9565% | 73.7705% | 30.4348% | 60.7843% | 155.5556% | 50% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-09-01 | 2026-06-12 | 2026-03-06 | 2025-12-01 | 2025-09-02 | 2025-06-13 | 2025-03-07 | 2024-12-02 | 2024-09-03 | 2024-06-14 |
| Amount | $0.43 | $0.43 | $0.43 | $0.43 | $0.43 | $0.43 | $0.43 | $0.42 | $0.42 | $0.42 |
Next Dividend Records
| Dividend per share (year): | $1.72 |
| Dividend Yield | 6.56% |
| Next Dividend Date | 2026-09-01 |
| Ex-Dividend Date | 2026-07-24 |
Recent News: PFE
2026-08-09 08:09:59
Beacon Investment Advisory Services Inc. significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by selling 9,055 shares, now holding 757 shares valued at $472,000. This comes as Regeneron reported strong quarterly earnings, surpassing analyst estimates, and maintains a "Moderate Buy" consensus rating with an average price target of $797.75. The company also declared a quarterly dividend of $0.94 per share, but faces ongoing securities litigation related to a failed Phase 3 melanoma trial.
2026-08-08 19:05:00
Pfizer will pay $44 million to settle a class-action lawsuit concerning its smoking-cessation drug Chantix, which allegedly contained an undisclosed nitrosamine. The settlement covers U.S. individuals and third-party payors who purchased Chantix between September 29, 2015, and September 17, 2021. Claimants must file by September 14, 2026, to receive compensation, with payments distributed proportionally based on purchase amounts.
2026-08-08 18:41:59
PTC Therapeutics, Inc. (PTCT) has received a "HOLD" investment rating from Argus, with a target price lowered to $79.00 from a current price of $73.31. The report highlights medium subratings for industry, financial strength, and value, while management, safety, and growth subratings are low. This assessment suggests a cautious outlook for the company's stock performance.
2026-08-08 17:11:14
This article summarizes recent analyst ratings for three healthcare stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO), and Pfizer (PFE). NRX Pharmaceuticals received a Strong Buy consensus with a $39.67 average price target. Novo Nordisk has a Hold consensus with a $44.33 average price target, indicating a slight downside, while Pfizer maintains a Hold consensus with an 8.2% upside potential based on its average price target of $28.38.
2026-08-08 15:40:07
Innoviva, Inc. reported a Q2 2026 net loss of US$83.42 million despite increased revenue, leading to a loss per share of US$1.14 from continuing operations. This quarterly loss contrasts with strong first-half net income, creating a volatile earnings picture. The company's recent US$66.40 million share buyback program, which retired 4.12% of shares, aims to return capital to shareholders amidst these fluctuating results and shifting market sentiment.
2026-08-08 15:02:47
This article reports on notable insider trading activity that occurred between August 3 and August 7, 2026, involving several major companies. Executives at Microsoft and Meta divested portions of their holdings, while insider purchases were observed in companies like Pfizer, Taiwan Semiconductor, and Tilray Brands. The trades varied in significance, with some sales and purchases representing a notable percentage of individual holdings.
